Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 18/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 11/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 11/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 11/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 14/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 13/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 12/20 | 0.41 |
| ▸ | PIM1 | P11309 | 11/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | CLK3 | P49761 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | DYRK4 | Q9NR20 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713650 | 1.00 | DYRK1A (0.41) | DYRK1ACSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL1714357 | 0.87 | AXL (0.41) | GSK3B | |
| SCHEMBL1714356 | 0.87 | AXL (0.41) | GSK3B | |
| SCHEMBL1713942 | 0.86 | JAK1 (0.35) | DYRK1ACSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL1713939 | 0.86 | JAK1 (0.35) | DYRK1ACSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL1714634 | 0.84 | BRD4 (0.36) | DYRK1ACSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL1714637 | 0.84 | BRD4 (0.36) | DYRK1ACSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL1714219 | 0.83 | CRHR1 (0.33) | — | |
| SCHEMBL1714215 | 0.83 | CRHR1 (0.33) | — | |
| SCHEMBL1714409 | 0.83 | PLK4 (0.33) | DYRK1ACSNK2A1CLK2CLK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| EP-2094699-B1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | CDC7, CDK7, CDK17 | DYRK1A 987/4885CSNK2A2 66/4885CSNK2B 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.